Key regulatory and legislative developments shaping U.S. healthcare and insurance in late 2025, including APTC expirations, CMS innovations, FDA initiatives, and congressional healthcare policy efforts.

Federal rescheduling of cannabis to Schedule III and a Medicare pilot program are set to advance U.S. healthcare integration, research, and institutional investment in cannabis-derived products.

CMS and FDA announce ACCESS and TEMPO initiatives to expand technology-enabled care for Medicare beneficiaries with chronic conditions, focusing on outcomes-based payments and regulatory enforcement discretion.

CMS and FDA have initiated the ACCESS Model and TEMPO pilot to expand technology-driven care for Medicare chronic condition patients, focusing on outcomes-based payments and regulatory flexibility.

CMS Innovation Center and FDA introduce ACCESS and TEMPO models to integrate digital health devices into Medicare, boosting care and payment innovation for chronic conditions.

FDA and CMS launch pilots to expand Medicare access to digital health technologies through outcome-aligned payments and regulatory flexibility, targeting chronic disease management.

CMS and FDA introduce ACCESS and TEMPO models to enable digital health device integration in traditional Medicare, focusing on outcome-aligned payments, regulatory easing, and expanded patient access.

An overview of key issues in U.S. health insurance, FDA regulatory inconsistencies, health care costs, anti-vaccine impacts, and emerging digital health policies affecting public health.

The Safe Food Coalition urges urgent regulatory action after a Clostridium botulinum outbreak linked to ByHeart infant formula reveals inspection gaps, stressing need for enhanced safety protocols in infant nutrition products.

Explore Medicare coverage guidelines for Botox focusing on FDA-approved medical uses, prior authorization, medical necessity, and cost factors under Medicare Part B and Advantage plans.